ClinicalTrials.Veeva

Menu

Impact of Respiratory Viral Infections in Infants With Cystic Fibrosis. (PREVIMUC)

Civil Hospices of Lyon logo

Civil Hospices of Lyon

Status

Completed

Conditions

Cystic Fibrosis
Respiratory Viral Infection

Treatments

Other: Physical assessment

Study type

Interventional

Funder types

Other

Identifiers

NCT02847156
69HCL14_0276

Details and patient eligibility

About

Respiratory Viral Infections (RVI) are particularly frequent in young children. Old data mention the deleterious role of some viruses such as the Respiratory Syncytial Virus in young children with cystic fibrosis (CF). However, recent epidemiological data on RVI in CF children are rare and the impact of most frequent viruses such as human rhinoviruses is usually not correctly evaluated.

The aim of this study is to assess the frequency of lower and upper RVI during a 1 year follow-up in CF infants and to evaluate the impact of RVI at a clinical, microbiological and therapeutic level.

Our hypothesis is that frequent and/or clinically severe RVIs have the worst impact in the short term and without any particular link with a specific virus as previously described.

Enrollment

25 patients

Sex

All

Ages

Under 24 months old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • infant <24 months with cystic fibrosis

Exclusion criteria

  • patient >24 months

Trial design

25 participants in 1 patient group

cystic fibrosis infants
Other group
Description:
1 year follow-up in CF infants
Treatment:
Other: Physical assessment

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems